Cancer Education and Research Institute
Worldwide Access to High-Quality Care, Research, and Education

United Nations, UNIATF Award 2019 Recipient

DONATE to support our programs
  • Home
    • About us >
      • About the Founder
    • Annual Reports and Media Kit
    • News Room >
      • CERI Press Releases 2025
      • CERI Press Releases 2022
      • CERI Press Releases 2021 >
        • Press Releases 2019 >
          • Press Releases 2020
      • Press Releases 2018
      • Press Releases 2017
      • Press Releases 2016
      • Press Releases 2015
      • Press Releases 2014
      • Press Releases 2013
    • Testimonials
  • MULTI-LANGUAGE CANCER BLOG
  • For Patients
    • CERI Personalized Patient Program™
    • All about cancer
    • Watch Our Cancer Videos >
      • Ovarian cancer diagnosis
    • Cancer Education
    • Our Publications >
      • Read CERI Simplified Cancer Research Articles
    • Cancer Types
    • Cancer detection and cancer treatment
    • Cancer Awareness Months
  • Events
  • Donate
    • Sponsorship levels
    • Membership
    • Become A Sponsor
    • Shop at CERI
    • Volunteer
    • Become a CERI Board Member
  • Contact us

BREAKING: FDA approves expanded indication for #Optune device with #temozolomide to treat #Glioblastoma (a form of #braincancer)

10/6/2015

0 Comments

 
Tweet
PicturePicture 1: Brain tumor patients can use the device at home or work; this will allow them to continue their normal daily activities.
October 5, 2015

The U.S. Food and Drug Administration (FDA) approved an expanded indication for the Optune device to treat patients with newly-diagnosed glioblastoma multiforme (GBM), an aggressive and deadly form of adult brain cancer. This medical device is used along with the chemotherapy drug temozolomide (TMZ) following standard treatments that include surgery, chemotherapy, and radiation therapy.

When using Optune, the neurosurgeon places electrodes on the surface of the patient’s scalp to deliver low-intensity, alternating electrical fields called “tumor treatment fields” (TTFields). The unique shape and special characteristics of rapidly dividing tumor cells make them susceptible to damage when exposed to TTFields, which could halt tumor growth.

"This is such wonderful news and a great milestone in the treatment of glioblastoma," said Dr. Ayguen Sahin, MSc, PhD, a brain cancer scientist, Founder and CEO of Cancer Research Simplified, a Boston-based, global cancer education nonprofit. "Glioblastoma multiforme or GBM is the most common, aggressive and deadly type of brain cancer in adults and it is highly resistant to therapies. It is great that this device can now be used as part of a standard treatment along with temozolomide, rather then being used as an adjunct therapy strategy."

Optune was initially approved in 2011 to treat patients with GBM that recurred or progressed after chemotherapy. With this expanded indication, Optune can be used as part of a standard treatment for GBM before the disease progresses.

Picture
Picture 2: Optune is a portable, non-invasive medical device designed for continuous use by patients.
The device is portable, carried by the patient in a backpack as seen in picture 2 above, and can be powered with batteries or plugged into an electrical outlet. Patients can use the device at home or work; this will allow them to continue their normal daily activities (see picture 1).

The FDA's approval is based on results from a clinical trial involving 695 patients newly diagnosed with GBM that compared those who used Optune with TMZ to those receiving TMZ alone.

Optune device +  TMZ = patients lived, on average, about seven months with no disease progression
TMZ alone = patients lived, four months

Optune device + TMZ = patients survived for an average of 19.4 months after diagnosis
TMZ = 16.6 months
Source: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465744.htm
Learn more about Optune: http://www.optune.com/HCP/therapy.aspx
Frequently Asked Questions (FAQ) about Optune: http://www.optune.com/resources/questions.aspx/
#novocure #optune #glioblastomamultiforme #glioblastoma #gbm #temozolomide #tmz #fda #cancer #braincancer

You may also like to read:
FDA grants Breakthrough Therapy Designation to Rindopepimut (Rintega)

Study linked decreased survival of Glioblastoma multiforme (GBM) patients with long-term use of mobile and cordless phones

0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Archives

    February 2025
    January 2025
    January 2024
    November 2023
    August 2023
    July 2023
    June 2023
    May 2023
    April 2023
    March 2023
    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    May 2020
    April 2020
    March 2020
    September 2019
    June 2019
    May 2019
    October 2018
    February 2017
    January 2017
    December 2016
    November 2016
    September 2016
    June 2016
    May 2016
    April 2016
    March 2016
    January 2016
    December 2015
    November 2015
    October 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013

    Categories

    All
    Cancer News
    Cancer News
    Cancer Research Simplified News
    Crs News
    Crs-news
    Holidays
    Quotes


Yes, I'd like to help CERI continue saving lives!
Become an 'Empowered Lifeline Supporter' with $20/month which is $0.66 per day!

Make a Monthly Contribution

Cancer Education and Research Institute® (formerly Cancer Research Simplified) is an independent 501(c)(3) non-profit organization.
Homepage 
Türkçe
Deutsch

About us
Meet the Founder
Meet the Team

News Room
Media Kit
Press Releases 
Watch Cancer Videos
Kanser videolarını izle
Krebs Videos ansehen
Cancer Resources

CERI Youth Program

Events

Shop at CERI


Ways to Help
Donate
Volunteer
Become A Sponsor

Blog
Blog-Deutsch
Blog-Türkçe
Blog-Afrikaans
Blog-Espanol
Blog-Italiano
Blog-Russkij
Blog-Portugues


Cancer Awareness Months



Stay Involved
Facebook
Twitter
Youtube
LinkedIn

Testimonials

Jobs

Contact Us
Cancer Research Simplified Homepage
Picture
Terms of Service
Privacy Policy
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Picture
Copyright © 2013-2025 Cancer Education and Research Institute®. All Rights Reserved. 
Sitemizdeki yazı, video ve resim her hakkı saklıdır. İzinsiz, kaynak gösterilmeden kullanılamaz.  
Alle Rechte vorbehalten.                             

Powered by Cancer Education and Research Institute®